Schaefers Johannes F, Schwindt Arne G, Maritati Gabriele, Torsello Giovanni, Pannucio Giuseppe
1 Department of Vascular and Endovascular Surgery, University of Münster, Münster, Germany.
2 Department of Vascular Surgery, St Franziskus-Hospital GmbH, Münster, Germany.
Vasc Endovascular Surg. 2018 Jan;52(1):27-33. doi: 10.1177/1538574417740057. Epub 2017 Oct 30.
The crossing of chronic total occlusions (CTOs) is the key step for an endovascular treatment. The Ocelot system is a novel device that combines a steerable drilling tip with optical coherence tomography (OCT) technology. It provides intraluminal imaging to help the crossing of CTOs in the femoropopliteal segment. Aim of the study was to determine early and midterm results after recanalization with this device.
During a period of 16 months, 84 CTOs were treated using the Ocelot system and prospectively registered. The primary end points were technical success and the primary and secondary patency of the lesion. Risk factors associated with early and midterm results were also analyzed. In all, 58 (69.0%) lesions were treated for intermittent claudication, 26 (31.0%) for critical limb ischemia, 34 (40.5%) were classified as Trans-Atlantic Inter-Society Consensus II D lesions, and 22 (26.2%) showed severe calcifications. The technical success rate was 72.6%. During 36 months of follow-up (mean 25.9), there were 10 reinterventions. The primary and secondary patency at 36 months were 54.2% and 68.1%, respectively.
In our experience, the Ocelot system would appear to be a safe and effective tool for increasing the applicability of endovascular techniques. However, the midterm results did not show drastic improvement.
慢性完全闭塞病变（CTO）的开通是血管内治疗的关键步骤。Ocelot系统是一种新型设备，它将可操控的钻孔尖端与光学相干断层扫描（OCT）技术相结合。它提供腔内成像以帮助开通股腘段的CTO。本研究的目的是确定使用该设备再通后的早期和中期结果。
在16个月的时间里，使用Ocelot系统治疗了84例CTO，并进行了前瞻性登记。主要终点是技术成功率以及病变的原发和继发通畅率。还分析了与早期和中期结果相关的危险因素。共有58例（69.0%）病变因间歇性跛行接受治疗，26例（31.0%）因严重肢体缺血接受治疗，34例（40.5%）被分类为跨大西洋两岸血管外科学会（TASC）II D级病变，22例（26.2%）显示严重钙化。技术成功率为72.6%。在36个月的随访期内（平均25.9个月），有10例再次干预。36个月时的原发和继发通畅率分别为54.2%和68.1%。
根据我们的经验，Ocelot系统似乎是一种安全有效的工具，可提高血管内技术的适用性。然而，中期结果并未显示出显著改善。
